<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The demethylating <z:chebi fb="0" ids="50131">5-aza-2'deoxycytidine</z:chebi> (DAC) and the <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor (HDACi) suberoyl <z:chebi fb="0" ids="13248">anilide</z:chebi> bishydroxamide (SAHA) possess potent antitumorigenic properties in myeloid disorders </plain></SENT>
<SENT sid="1" pm="."><plain>However, the transcriptome alterations mediated by these drugs are poorly understood </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed the transcriptional effects of DAC and SAHA in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell line KG-1 </plain></SENT>
<SENT sid="3" pm="."><plain>Microarray analyses revealed 76 genes expressed in <z:mpath ids='MPATH_458'>normal</z:mpath> CD34+ cells, absent in KG-1 cells but whose expression was induced after drug treatment </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 39 of these genes harbored CpG islands in their promoters </plain></SENT>
<SENT sid="5" pm="."><plain>We examined the expression level of these genes in 120 AML patient samples representing diverse karyotpyes </plain></SENT>
<SENT sid="6" pm="."><plain>Gas2l1, tfIIs, ehd3, enolase 2, mx1, dral, astml and pxdn were diminished across <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> karyotypes examined </plain></SENT>
<SENT sid="7" pm="."><plain>Ehd3 was methylated in 63% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients examined </plain></SENT>
<SENT sid="8" pm="."><plain>This methylation was lost upon complete remission, and not observed in <z:mpath ids='MPATH_458'>normal</z:mpath> CD34+ cells </plain></SENT>
<SENT sid="9" pm="."><plain>CD34+ cells expressed ehd3 at approximately 10-fold higher levels than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> samples </plain></SENT>
<SENT sid="10" pm="."><plain>Another highlighted gene, alpha-catenin, is located at q31 of chromosome 5 </plain></SENT>
<SENT sid="11" pm="."><plain>Analyses of 29 5q- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) samples revealed marked decreases in expression of alpha-catenin, compared to non-5q- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> samples (6.6+/-9-fold) </plain></SENT>
<SENT sid="12" pm="."><plain>However, no methylation was detected, suggesting indirect effects of these drugs on the expression of alpha-catenin </plain></SENT>
</text></document>